Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings.
Zheng SL., Jurgens SJ., McGurk KA., Xu X., Grace C., Theotokis PI., Buchan RJ., Francis C., de Marvao A., Curran L., Bai W., Pua CJ., Tang HC., Jorda P., van Slegtenhorst MA., Verhagen JMA., Harper AR., Ormondroyd E., Chin CWL., HCM GWAS Collaborators None., Pantazis A., Baksi J., Halliday BP., Matthews P., Pinto YM., Walsh R., Amin AS., Wilde AAM., Cook SA., Prasad SK., Barton PJR., O'Regan DP., Lumbers RT., Goel A., Tadros R., Michels M., Watkins H., Bezzina CR., Ware JS.
Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality, with pathogenic variants found in about a third of cases. Large-scale genome-wide association studies (GWAS) demonstrate that common genetic variation contributes to HCM risk. Here we derive polygenic scores (PGS) from HCM GWAS and genetically correlated traits and test their performance in the UK Biobank, 100,000 Genomes Project, and clinical cohorts. We show that higher PGS significantly increases the risk of HCM in the general population, particularly among pathogenic variant carriers, where HCM penetrance differs 10-fold between those in the highest and lowest PGS quintiles. Among relatives of HCM probands, PGS stratifies risks of developing HCM and adverse outcomes. Finally, among HCM cases, PGS strongly predicts the risk of adverse outcomes and death. These findings support the broad utility of PGS across clinical settings, enabling tailored screening and surveillance and stratification of risk of adverse outcomes.